Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: A prospective randomized study

Epilepsia

Volumn 54, Issue 1, 2013, Pages 45-57

  Fuller, Karen L ^a   Wang, Yi Yuen ^a,b   Cook, Mark J ^a   Murphy, Michael A ^a   D'Souza, Wendyl J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adverse events; Antiepileptic drugs; Clinical trials; Neurosurgical seizure prophylaxis; Parenteral

Indexed keywords

ETIRACETAM; PHENYTOIN;

ADULT; AGED; ALLERGIC REACTION; ANAPHYLAXIS; ARTICLE; ASTHENIA; ATAXIA; BREAST CANCER; CONTROLLED STUDY; CRANIOTOMY; DELIRIUM; DISEASE SEVERITY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HOSPITAL DISCHARGE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; NEUROSURGERY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; THROMBOPHLEBITIS; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; CRANIOTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENYTOIN; PIRACETAM; SEIZURES;

EID: 84872071854     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2012.03563.x     Document Type: Article

References (59)

1. Appleton RE, Gill A,. (2003) Adverse events associated with intravenous phenytoin in children: a prospective study. Seizure 12: 369-372.
2. Baulac M, Brodie MJ, Elger CE, Krakow K, Stockis A, Meyvisch P, Falter U,. (2007) Levetiracetam intravenous infusion as an alternative to oral dosing in patients with partial-onset seizures. Epilepsia 48: 589-592.
3. Beenen LFM, Lindeboom J, Kasteleijn-Nolst, Trenite DGA, Heimans JJ, Snoek FJ, Touw DJ, Ader HJ, van Alphen HAM,. (1999) Comparative double blind clinical trial of phenytoin and sodium valproate as anticonvulsant prophylaxis after craniotomy: efficacy, tolerability, and cognitive effects. J Neurol Neurosurg Psychiatry 67: 474-480.
4. Ben-Menachem E, Falter U, for the European Levetiracetam Study Group. (2000) Efficacy and tolerability of levetiracetam 3000mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41: 1276-1283.
5. Berning S, Boesebeck F, van Baalen A, Kellinghaus C,. (2009) Intravenous levetiracetam as treatment for status epilepticus. J Neurol 256: 1634-1642.
6. Betts T, Waegemans T, Crawford P,. (2000) A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy. Seizure 9: 80-87.
7. Beyenburg S, Reuber M, Maraite N,. (2009) Intravenous levetiracetam for epileptic seizure emergencies in older people. Gerontology 55: 27-31.
8. Binder L, Grujillo J, Parker D, Cuetter A,. (1996) Association of intravenous phenytoin toxicity with demographic, clinical, and dosing parameters. Am J Emerg Med 14: 398-401.
9. Bird JM, Joseph ZA,. (2003) Levetiracetam in clinical use-a prospective observational study. Seizure 12: 613-616.
10. Briggs DE, French JA,. (2004) Levetiracetam safety profiles and tolerability in epilepsy patients. Expert Opin Drug Saf 3: 415-424.
11. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke H-J, Levetiracetam Monotherapy Study Group. (2007) Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68: 402-408.
12. Browne T,. (1998) Intravenous phenytoin: cheap but not necessarily a bargain. Neurology 51: 942-943.
13. Burneo JG, Anandan JV, Barkley GL,. (2001) A prospective study of the incidence of the purple glove syndrome. Epilepsia 42: 1156-1159.
14. Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik I, and the United States Levetiracetam Study Group. (2000) Levetiracetam for partial seizures. Results of a double-blind, randomized clinical trail. Neurology 55: 236-242.
15. Chung S, Wang N, Hank N,. (2007) Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16: 296-304.
16. Coplin WM, Rhoney DH, Rebuck JA, Clements EA, Cochran MS, O'Neil BJ,. (2002) Randomized evaluation of adverse events and length-of-stay with routine emergency department use of phenytoin or fosphenytoin. Neurol Res 24: 842-848.
17. Cox DR,. (1972) Regression models and life tables. J R Stat Soc 34: 187-220.
18. Crepeau AZ, Treiman DM,. (2010) Levetiracetam: a comprehensive review. Expert Rev Neurother 10: 159-171.
19. De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E,. (2002) Add-on Phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 43: 175-182.
20. Delattre J-Y, Safai B, Posner J,. (1988) Erythema multiforme and Stevens-Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 38: 194-198.
21. Depondt C, Yuen AWC, Bell GS, Titchell T, Koepp MJ, Duncan JS, Sander JW,. (2005) The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 77: 101-103.
22. Depondt C, Godard P, Espel RS, Da Cruz AL, Lienard P, Pandolfo M,. (2011) A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity. Eur J Neurol 18: 1159-1164.
23. DeToledo JC, Ramsay RE,. (2000) Fosphenytoin and phenytoin in patients with status epilepticus. Improved tolerability versus increased costs. Drug Saf 22: 459-466.
24. Earnest MP, Marx JA, Drury LR,. (1983) Complications of intravenous phenytoin for acute treatment of seizures. JAMA 249: 762-765.
25. Foy PM, Chadwick DW, Rajgopalan N, Johnson AL, Shaw MDM,. (1992) Do prophylactic anticonvulsant drugs alter the pattern of seizures after craniotomy?. J Neurol Neurosurg Psychiatry 55: 753-757.
26. Goraya JS, Khurana DS, Valencia I, Melvin JJ, Cruz M, Legido A, Kolthare SV,. (2008) Intravenous levetiracetam in children with epilepsy. Paediatr Neurol 38: 177-180.
27. Harden C,. (2001) Safety profile of levetiracetam. Epilepsia 42: 36-39.
28. Henkin SA, Knapp LE, Smith MF, Baron BA,. (1996) Tolerance of intravenous fosphenytoin (Cerebyx) compared with Dilantin: an overview of 3 studies (Abstract). Epilepsia 37: 157.
29. Klimek M, Dammers R,. (2010) Antiepileptic drug therapy in the perioperative course of neurosurgical patients. Curr Opin Anaesthesiol 23: 564-567.
30. Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, Harner HM, Rosenow F,. (2007) Intravenous levetiracetam in the treatment of benzodiazepine-refractory status epilepticus. J Neurol Neurosurg Psychiatry 78: 588-589.
31. Kuijlen JMA, Teernstra OPM, Kessels AGH, Herpers MJHM, Beuls EAM,. (1996) Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 5: 291-298.
32. Lawson LA, Bloain RA, Smith RB, Rapp RP, Young AB,. (1981) Phenytoin-dexamethasone interaction: a previously unreported observation. Surg Neurol 16: 23-24.
33. Mamon HJ, Wen PY, Burns AC, Loeffler JS,. (1999) Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 40: 341-344.
34. Martinelli EF, Muhlebach SF,. (2003) Rapid i.v. loading with phenytoin with subsequent dose adaptation using non-steady-state serum levels and a Bayesian forecasting computer program to predict maintenance doses. J Clin Pharm Ther 28: 385-393.
35. Mattson RH,. (1996) Parenteral antiepileptic/anticonvulsant drugs. Neurology 46: S8-S13.
36. Milligan TA, Hurwitz S, Bromfield EB,. (2008) Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. Neurology 71: 665-669.
37. Moddel G, Bunten S, Dobis C, Kovac S, Dogan M, Fischera M, Dziewas R, Schabitz W-R, Evers S, Happe S,. (2009) Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. J Neurol Neurosurg Psychiatry 80: 689-692.
38. Naidech AM, Kreiter KT, Janjua N, Ostapkovich N, Parra A, Commichau C, Connoly ES, Mayer SA, Fizsimmons B-FM,. (2005) Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 36: 583-587.
39. Naidech AM, Garg RK, Liebling S, Levasseur K, Macken MP, Schuele SU, Batjer HH,. (2009) Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke 40: 3801-3815.
40. Newton HB, Goldlust SA, Pearl S,. (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78: 99-102.
41. Newton HB, Dalton J, Goldlust S, Pearl D,. (2007) Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors. J Neurooncol 84: 293-296.
42. Ng Y-T, Hastriter EV, Cardenas JF, Khoury EM, Chapman KE,. (2010) Intravenous levetiracetam in children with seizures: a prospective safety study. J Child Neurol 25: 551-555.
43. O'Brien TJ, Meara FM, Matthews H, Vajda FJ,. (2001) Prospective study of local cutaneous reactions in patients receiving IV phenytoin. Neurology 57: 1508-1510.
44. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, Stockis A,. (2006) Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 47: 1128-1135.
45. Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, Mao L, Wiegand F, Hulihan J, for the CAPSS-272 Study Group. (2010) Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 51: 1970-1977.
46. Rossetti AO, Stupp R,. (2010) Epilepsy in brain tumour patients. Curr Opin Neurol 23: 603-609.
47. Ruegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P,. (2008) Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 12: 47-480.
48. Shorvon SD, Lowenthal A, Janz D, Bielen E, Loiseau P, for the European Levetiracetam Study Group. (2000) Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41: 1179-1186.
49. Spengler RF, Arrowsmith JB,. (1988) Severe soft tissue injury following intravenous infusion of phenytoin: patient and drug administration risk factors. Arch Intern Med 148: 1329-1333.
50. Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA,. (2010) Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 12: 165-172.
51. Temkin NR, Kikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR,. (1990) A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 323: 497-502.
52. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay RE, Mamdani MB, for the Veterans Affairs Status Epilepticus Cooperative Study Group. (1998) A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 339: 792-798.
53. Trinka E, Dobesberger J,. (2009) New treatment options in status epilepticus: a critical reveiw on intravenous levetiracetam. Ther Adv Neurol Disord 2: 79-91.
54. Twardowschy CA, De Paola L, Germiniani FMB, Werneck LC, Silvado C,. (2009) Pearls and Oy-sters: soft-tissue necrosis as a result of intravenous leakage of phenytoin. Neurology 73: e94-e95.
55. Usery JB, Michael LM II, Sills AK, Finch CK,. (2010) A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 99: 251-260.
56. Vecht CJ, Wilms EB,. (2010) Seizures in low- and high-grade gliomas: current management and future outlook. Expert Rev Anticancer Ther 10: 663-669.
57. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L,. (2006) Medical management of patients with brain tumors. J Neurooncol 80: 313-332.
58. Yap KY-L, Chui WK, Chan A,. (2008) Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther 30: 1385-1407.
59. Zachenhofer I, Donat M, Oberndorfer S, Roessler K,. (2011) Perioperative levetiracetam for prevention of seizures in supratentorial brain tumor surgery. J Neurooncol 101: 101-106.